Apply Now

News » Archives » October 2011

New technology helps ER doctors make critical decisions

Author: William G. Gilroy

Emergency room

Researchers from the University of Notre Dame’s Keck Center for Transgene Research and trauma physicians at South Bend’s Memorial Hospital are joining forces to use a new medical technology to help save the lives of trauma patients.

Researchers at the Keck Center investigate how the genes involved in blood clotting processes function in inflammatory diseases like sepsis, atherosclerosis and asthma. In particular, the Center’s Thromboelastographic Study Group focuses on the coagulopathy (clotting disorder or bleeding disorder) of trauma. Read More

Notre Dame researchers lead collaborative team to study bacteria movement

Author: Paul Murphy

Mark Alber

An interdisciplinary collaboration of six researchers, including four from Notre Dame, have received a three-year National Institutes of Health (NIH) grant to study the interplay of motility mechanisms during swarming of the bacterium Myxococcus xanthus. Their study is essential to understanding how millions of bacteria function in real environments.

Mark Alber, the Vincent J. Duncan Family Professor of Applied Mathematics and director of the Center for Study of Biocomplexity at the University of Notre Dame, is principal investigator of the team. Read More

Notre Dame cancer researcher named V Scholar

Author: Paul Murphy

Zachary Schafer

Zachary Schafer, the Coleman Assistant Professor of Cancer Biology in the Department of Biological Sciences and a member of the Harper Cancer Research Institute at the University of Notre Dame, has been named a 2011 V Scholar by one of the nation’s leading cancer research fundraising organizations, the V Foundation for Cancer Research. Seventeen physician/scientists will share the $3.4 million in funding given through the V Scholar program to bring science closer to finding a cure for cancer.

Through a very competitive process, Schafer was chosen from nominees at National Cancer Institute (NCI)-designated cancer centers and prominent universities involved in critical cancer research. Read More

Controlling gene expression to halt cancer growth

Author: Paul Murphy

Olaf Wiest

NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.

But difficult doesn’t mean impossible, and Olaf Wiest, professor of chemistry and biochemistry at the University of Notre Dame, is one of a group of collaborators studying the effects of a specific molecule (JQ1) on the trigger that controls the growth of this form of cancer. Read More

Notre Dame researchers make neurological disease breakthrough

Author: William G. Gilroy

Prodrug ND-478 being processed to ND-322 in blood vessels

Results of a study by a group of University of Notre Dame researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases.

The group from the University’s Departments of Chemistry and Biochemistry and Biological Sciences and the Freimann Life Sciences Center focused on the design, synthesis and evaluation of water-soluble “gelatinase inhibitor” compounds. Read More